During Monday’s Current trade, Shares of UBS Group AG (USA) (NYSE:UBS), lost -0.92% to $18.22.
As part of its ongoing commitment to service excellence for both plan sponsors and participants, UBS Wealth Administration Americas, a partner of UBS Group AG, has developed a new feature for its Equity Plan Advisory Services (EPAS) offering: the Modeling and Forecasting module in Financials Online, UBS’s web-based financial reporting and analysis tool for plan sponsors, which supports corporate clients’ compliance with accounting rules for share-based compensation under FASB ASC 718.
This enhancement follows several recent innovative releases, counting the UBS One Source Mirror, a proprietary co-browsing solution that allows both the plan sponsor and the UBS service team to assist participants with their questions about the UBS One Source platform by viewing, in real time, what they see on their computer screens or mobile devices.
The new modeling and forecasting capabilities in Financials Online offer an additional enhancement to UBS’s robust financial reporting platform, which not only aids corporate plan sponsors with ASC 718 compliance, but also allows them to forecast future periods, counting expense and earnings per share values. UBS Wealth Administration Americas has hosted several well-attended plan sponsor training sessions as part of the product release.
UBS Group AG, together with its auxiliaries, provides wealth administration, retail and corporate, asset administration, and investment banking products and services worldwide. The company’s Wealth Administration division provides financial services to wealthy private clients.
Shares of Lincoln National Corporation (NYSE:LNC), declined -2.73% to $46.68, during its current trading session.
Lincoln Financial Group (LNC) declared that it will report its third quarter earnings after market close on Wednesday, October 28, 2015. A conference call is planned for Thursday, October 29, 2015, at 10:00 a.m. Eastern Time, to talk about third quarter earnings and related matters for the company and its business segments.
Lincoln National Corporation, through its auxiliaries, engages in multiple insurance and retirement businesses in the United States. It operates through Annuities, Retirement Plan Services, Life Insurance, and Group Protection segments.
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), during its Monday’s current trading session decreased -1.79% to $2.19.
Navidea Biopharmaceuticals Inc., (NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents, recently declared that Navidea’s common stock, which began trading on the Tel-Aviv Stock Exchange (“TASE”) on September 8, 2015, will be comprised of, effective October 6, 2015, in the following major TASE indexes: TA-100, TA-75, TA-Composite, TA-Biomed, TA-BlueTech and TA-Tech-Elite.
Navidea Biopharmaceuticals, Inc., a precision medicine company, focuses on the development and commercialization of precision diagnostics, therapeutics, and radiopharmaceutical agents.
Finally, Synthetic Biologics Inc (NYSEMKT:SYN), decreased -10.92%, to $2.61.
Synthetic Biologics, Inc. (SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, stated the initiation of its SYN-004 Phase 2b proof-of-concept clinical trial. The clinical trial is intended to evaluate the effectiveness of SYN-004 to prevent C. difficile infection (CDI), C. difficile associated diarrhea (CDAD) and antibiotic-associated diarrhea (AAD) in patients hospitalized for a lower respiratory tract infection and receiving intravenous (IV) ceftriaxone.
Synthetic difficile is the leading type of hospital attained infection and is frequently associated with IV antibiotic treatment. Beta-lactam antibiotics are a mainstay in hospital infection administration, and comprise commonly used penicillin and cephalosporin antibiotics, such as ceftriaxone. However, antibiotics have the potential to cause harmful effects within the gastrointestinal (GI) tract counting disruption of the natural balance of the gut microbiome, leading to 1.1 million CDIsi and 30,000 C. difficile-related deathsii in the United States each year.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
